Regenerative Medicine

As the National Academy of Medicine's $1.5M competition concludes, a novel biologic targeting muscle loss challenges how we treat human aging.

NurExone Biologic reports statistically significant preclinical data for its exosome therapy, taking a crucial step toward reversing optic nerve damage.

LELO's new MONA Spectra merges skincare's photobiomodulation with intimate wellness, signaling a strategic shift toward regenerative pelvic self-care.

A breakthrough gene therapy restores natural hearing in children, challenging mechanical implants and reshaping the economics of genomic medicine.

BioCardia’s revised FDA submission for its Helix catheter could set a new regulatory standard and unlock lucrative biopharma partnerships.

French biotech EVerZom successfully completes preclinical studies for its exosome-based EVerGel, targeting a 2027 clinical debut for Crohn's disease fistulas.

With a unique off-the-shelf stem cell therapy, BOOST Pharma is poised to reshape pediatric care for osteogenesis imperfecta as it seeks Phase III partners.

NanoTess co-founders Megan Leslie and Julian Mulia win Canada's Top 40 Under 40 for a catalytic technology that addresses a massive healthcare crisis.

A late-stage biotech is betting on a novel idea: what if we could repair eye damage at a structural level? Stuart Therapeutics' PolyCol™ platform aims to do just that.

Axiom Biosciences' pact with CDMO GeneFab isn't just a deal; it's a strategic necessity to scale its promising therapies from the lab to patients.

With new backing from specialist fund SCI Ventures, ViaNautis is deploying its novel gene delivery platform to develop regenerative therapies for paralysis.

An Australian firm is tackling a growing allergy risk in medical implants. Their work on the α-Gal epitope could be key to the future of tissue engineering.

As Claris Bio courts investors, it's not just capital on the line. At stake is a first-of-its-kind eye drop for a rare, blinding disease.

The Israeli biotech firm gained crucial FDA feedback for its personalized therapy, NewRal. But in a field laden with failure, is this a true breakthrough?

Thai researchers are turning fat into insulin-producing cells to cure pet diabetes. But can this breakthrough navigate the path from lab to leash?

A German biotech's novel drug just won a key FDA designation, a strategic move that could redefine the limits of liver surgery and cancer treatment.

As Mesoblast prepares its year-end webcast, investors weigh a stellar $115M Ryoncil launch against cash burn and the high-stakes progress of its next-gen therapies.

A proposed SXSW panel on longevity medicine forces a crucial question: Are we on the verge of restoring youth, or just drowning in promises? We look at the science.

BioLab Holdings partners with mimiX AWC, bringing a radical new technology to market that uses a patient's own blood to create a living, healing patch.

New preclinical data shows NurExone's ExoPTEN protects vital nerve coatings, providing a biological basis for functional recovery in spinal cord injury models.